SCHEMBL6446232

SCHEMBL6446232

COC(=O)CCCCC(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.48
PLA2G2A P14555 1/20 0.47
PLA2G5 P39877 1/20 0.47
TSHR P16473 3/20 0.47
SDCBP O00560 2/20 0.43
SDC2 P34741 2/20 0.43
RECQL P46063 1/20 0.43
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
MEN1 O00255 1/20 0.41
FAAH O00519 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
MBTPS1 Q14703 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622468 1.00 EPHX2 (0.48) EPHX2PLA2G2APLA2G5TSHRSDCBP
SCHEMBL621625 0.98 EPHX2 (0.50) EPHX2PLA2G2APLA2G5TSHRSDCBP
SCHEMBL621624 0.98 EPHX2 (0.50) EPHX2PLA2G2APLA2G5TSHRSDCBP
SCHEMBL6445088 0.98 EPHX2 (0.50) EPHX2PLA2G2APLA2G5TSHRSDCBP
SCHEMBL6445084 0.98 EPHX2 (0.50) EPHX2PLA2G2APLA2G5TSHRSDCBP
SCHEMBL6444837 0.94 EPHX2 (0.44) EPHX2PLA2G2APLA2G5TSHRSDCBP
SCHEMBL15623788 0.89 PLA2G2A (0.56) EPHX2PLA2G2APLA2G5SDCBPSDC2
SCHEMBL28345863 0.87 TSHR (0.44) EPHX2PLA2G2APLA2G5TSHRRECQL
SCHEMBL28345864 0.87 TSHR (0.44) EPHX2PLA2G2APLA2G5TSHRRECQL
SCHEMBL28806410 0.86 TSHR (0.47) TSHRRECQLALDH1A1MEN1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050130941-A1 Methods of treating alzheimer's disease PHARMACIA & UPJOHN COMPANY LLC 2005-06-16 US disclosed
EP-1392315-A1 METHODS OF TREATING ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-03-03 EP disclosed
WO-2002100410-A1 METHODS OF TREATING ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-12-19 WO disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 US disclosed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 EP disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130941-A1 Methods of treating alzheimer's disease BACE1, PSEN1, BACE2 EPHX2 1638/4885PLA2G2A 2270/4885PLA2G5 1274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.